胚系突变在胸部恶性肿瘤中的作用:神话与现实之间
综述探讨胸部恶性肿瘤中胚系突变的作用,指出环境因素已明确而遗传易感性研究较少。接受下一代测序的非小细胞肺癌患者中致病性胚系变异检出率为2%至3%,胸膜间皮瘤相关胚系突变比例在不同研究间差异大,介于5%至10%。综述总结了致病机制、临床特征、治疗意义及高危个体筛查建议。
要点
- 接受下一代测序分析的非小细胞肺癌患者中,致病性胚系变异检出率为2%至3%。
- 胸膜间皮瘤中与发病相关的胚系突变比例在不同研究间差异较大,介于5%至10%。
- 综述聚焦胸部恶性肿瘤胚系突变的致病机制、临床特征、治疗意义及高危个体筛查建议。
核心结论
- 综述总结了胸部恶性肿瘤胚系突变的新兴证据,聚焦致病机制、临床特征、治疗意义及高危个体筛查建议。
研究设计与样本
- 综述,总结胸部恶性肿瘤胚系突变的新兴证据。
主要发现
- 接受下一代测序分析的非小细胞肺癌患者中,致病性胚系变异检出率为2%至3%。
- 与胸膜间皮瘤发病相关的胚系突变比例在不同研究间差异较大,介于5%至10%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Considering the established contribution of environmental factors to the development of thoracic malignancies, the inherited susceptibility of these tumors has rarely been explored. However, the recent introduction of next-generation sequencing-based tumor molecular profiling in the real-word setting enabled us to deeply characterize the genomic background of patients with lung cancer with or without smoking-related history, increasing the likelihood of detecting germline mutations with potential prevention and treatment implications. Pathogenic germline variants have been detected in 2% to 3% of patients with NSCLC undergoing next-generation sequencing analysis, whereas the proportion of germline mutations associated with the development of pleural mesothelioma widely varies across different studies, ranging between 5% and 10%. This review provides an updated summary of emerging evidence about germline mutations in thoracic malignancies, focusing on pathogenetic mechanisms, clinical features, therapeutic implications, and screening recommendations for high-risk individuals.
引用
- Farinea G, Crespi V, Listì A, et al. The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality. J Thorac Oncol. 2023. PMID: 37331604. doi:10.1016/j.jtho.2023.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。